
Co-located with

Now in its 9th edition, Cell and Gene Therapy World Asia has firmly established itself as Asia’s leading cell and gene therapy gathering for new partnerships, ideas, and knowledge. We are proud to continue providing a platform where Asia’s rapidly growing CGT industry takes center stage, attracting increasing global attention for its fast-paced advancements in new therapies, R&D, and biomanufacturing.
Key Themes & Topics
What to Expect at the 9th Annual Cell & Gene Therapy World Asia 2025

Attendees
Join over 300 professionals at the 9th Annual Cell & Gene Therapy World Asia! Connect with key industry players, expand your network, and engage in high-level discussions shaping the future of biologics.

Companies
Meet 100 leading companies driving innovation in the biologics sector. Whether you're seeking new partners or exploring the latest breakthroughs, this is the ideal platform to discover what’s next in the industry.

Speakers
Gain exclusive insights from 50 expert speakers shaping the future of biologics. Learn from the best in the field as they share cutting-edge knowledge, practical solutions, and emerging trends you won’t want to miss.
Testimonials
Into its 9th edition, Cell and Gene Therapy World Asia has firmly established itself as Asia's THE cell and gene therapy gathering for new partnerships, ideas and knowledge. We are proud to continue the meeting platform where Asia's growing cell and gene therapy industry is at the forefront, receiving more and more global attention on its fast advancement in new therapies, R&D and biomanufacturing.
WHO
C-suites, Heads, Presidents, Directors, and VPs of R&D, Process Development, Manufacturing, Cell & Gene Therapy, Regenerative Medicine, and Quality Control & Assurance from cell and gene therapy companies across Asia and globally.
WHAT
Evaluate best practices, latest strategies, technologies, and solutions for building high-quality cell and gene therapy treatments through clinical trials and market pathways in Asia.
WHY
APAC contributed over 26% of global CGT revenue in 2021, with the market projected to grow to US$4 billion by 2027 at a 21% CAGR. Cell & gene biomanufacturing is also rising fast, expected to reach US$8.6 billion by 2031. Strong investment across government, pharma, and academia is driving innovation and demand for advanced manufacturing solutions.
CONTACT
Ana Laxamana, Business Development Manager
m: +65 6983 6132
Nathan Grace Niño, Business Development Manager
m: +65 6983 6134 | +44 161 552 8521

Share With Your Network
